<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830595</url>
  </required_header>
  <id_info>
    <org_study_id>PCC-006</org_study_id>
    <nct_id>NCT01830595</nct_id>
  </id_info>
  <brief_title>Lactoferrin Treatment in HIV Patients</brief_title>
  <official_title>Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jason Baker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ventria Bioscience</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Minneapolis Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin
      (1500mg bid) for reducing inflammation among HIV positive participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>3 months</time_frame>
    <description>Self reported side effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation and Coagulation</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in markers of systemic inflammation (e.g., IL-6) and coagulation (e.g., D-dimer) will be compared between treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 Months</time_frame>
    <description>DAIDS criteria will be used for grading adverse events (serious and non-serious)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Monocyte Activation</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Tissue Factor Activity</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Recombinant Lactoferrin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant lactoferrin will be administered by mouth twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo will be administered by mouth twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Lactoferrin</intervention_name>
    <arm_group_label>Recombinant Lactoferrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-positive participants receiving ART for &gt;1 year

          2. HIV RNA level &lt;200 copies/mL for at least 6 months (â‰¥2 separate values)

          3. Age &gt;40 years

        Exclusion Criteria:

          1. Prior cardiovascular disease or stroke

          2. Diabetes

          3. Rheumatologic Diseases

          4. Pregnancy

          5. Chronic kidney disease, stage IV or V (creatinine clearance &lt;30 mL/min/1.73m2)

          6. Cirrhosis or end-stage liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Minneapolis Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Jason Baker</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactoferrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

